Business your connection to The Boston Globe

Wider shield found in cancer vaccine

Gardasil blocks most infections by HPV, Merck says

TRENTON, N.J. - New data shows a vaccine against the virus that causes cervical cancer partially blocks infection by 10 strains of the virus on top of the four types the vaccine targets.

That boosts protection - at least partially - to 90 percent of strains causing the deadly cancer, according to data presented yesterday at a medical conference by Merck & Co., maker of Gardasil.

Whitehouse Station-based Merck called it the first evidence of any vaccine providing cross-protection against other strains of the human papilloma virus, or HPV.

Dr. Stephanie Blank, a gynecologic oncologist at the NYU Cancer Institute, said the finding could encourage more widespread use of Gardasil in developing countries, where some of the additional strains are more widespread and women rarely get Pap smears to detect early, curable cancers.

Gardasil is the only cervical cancer vaccine on the market. It is approved for sale in 85 countries and pending approval in 40 more and has about $1 billion in sales since its June 2006 US launch. GlaxoSmithKline PLC is awaiting approval of its vaccine, Cervarix.

There are more than 60 strains of the HPV virus. About 15 are thought to cause cervical cancer; Gardasil protects against 12 of those, plus another two that cause genital warts but not cancer.

Two strains cause 70 percent of cervical cancer. Merck studies following 17,600 young women for three years found the vaccine to be 99 percent effective in blocking those strains.

New analysis of that data shows the vaccine reduced incidence of HPV-caused precancerous lesions by nearly two-thirds for the three next most common HPV strains in North America. While those three strains are less common elsewhere, together they cause about 11 percent of cervical cancer worldwide.

"There's the potential for an additional 30,000 to 40,000 cancer cases being prevented each year," mostly in developing countries, based on preliminary estimates and widespread vaccination in those regions, said Dr. Eliav Barr, head of Merck's research on infectious disease and vaccines.

There are 9,710 new cases of cervical cancer and 3,700 deaths in the United States each year. Worldwide, there are nearly 500,000 new cases and 233,000 deaths a year.

More from